Healthcare Unfiltered Express Podcast By Chadi Nabhan cover art

Healthcare Unfiltered Express

Healthcare Unfiltered Express

By: Chadi Nabhan
Listen for free

Healthcare Unfiltered Express curates quick-hit conversations between Dr. Chadi Nabhan and his guests on hot-button topics in the healthcare world today.

© 2026 Healthcare Unfiltered Express Hygiene & Healthy Living Physical Illness & Disease
Episodes
  • Episode 51: Treating Relapsed/Refractory CLL

    Episode 51: Treating Relapsed/Refractory CLL
    Apr 27 2026

    Dr. Matt Davids of the Dana Farber Cancer Institute joins Healthcare Unfiltered EXPRESS to share his data-solidified insights on navigating the treatment of relapsed/refractory (R/R) CLL, considering the welcome advances the field has witnessed in treating front-line disease. Check it out, subscribe, rate, and join the conversation.
    Show more Show less
    11 mins
  • The MajesTEC-3 Trial in Myeloma

    The MajesTEC-3 Trial in Myeloma
    Apr 12 2026

    Dr. Vincent Rajkumar of the Mayo Clinic joins the Healthcare Unfiltered EXPRESS to highlight a major study recently published in the NEJM concerning patients with R/R multiple myeloma. This study is arguably changing the standard of care for relapsed disease. We discussed the study, its rationale, its implications, and limitations.

    Here is a link to the actual publication: https://www.nejm.org/doi/full/10.1056/NEJMoa2514663

    Please subscribe, rate, share, review, and join the conversation.
    Show more Show less
    11 mins
  • Episode 49: Bladder Cancer Updates From ASCO GU 2026

    Episode 49: Bladder Cancer Updates From ASCO GU 2026
    Mar 30 2026

    Dr. Andrea Apolo from the NCI and the co-Chair of the ASCO GU 2026 scientific program joined the Healthcare Unfiltered EXPRESS to share what she viewed as potentially practice-changing data in bladder cancer. She discussed what she viewed as the top 4 abstracts to be aware of.

    Stay up to date on all oncology meetings by subscribing to Healthcare Unfiltered EXPRESS; share with colleagues, and join the conversation.
    Show more Show less
    14 mins
No reviews yet